Phase 2b RCT in 165 patients with IPF-associated chronic cough (160 analysed): nalbuphine ER 27, 54 and 108 mg twice daily reduced 24-h cough frequency by 47.9%, 53.4% and 60.2% at 6 weeks v 16.9% with placebo; the 2 higher doses improved patient-reported cough.
RCTn = 165
Molyneaux et al. Oral Nalbuphine in Idiopathic Pulmonary Fibrosis-Associated Cough: The CORAL Randomized Clinical Trial